ABC | Volume 113, Nº1, Julho 2019

Posicionamento Posicionamento sobre Antiagregantes Plaquetários e Anticoagulantes em Cardiologia – 2019 Arq Bras Cardiol. 2019; 113(1):111-134 Tabela 14 – Recomendações para uso de antiagregantes plaquetários e anticoagulantes em pacientes oncológicos com trombocitopenia Indicações Classe de recomendação Nível de evidência Uso do ácido acetilsalicílico em pacientes com doença coronária I A Uso de clopidogrel e ácido acetilsalicílico em associação em pacientes com síndrome coronária aguda de alto risco ou após angioplastia coronária I A O ácido acetilsalicílico deve ser usado sempre em dose mínima, preferencialmente ≤ 100 mg ao dia IIa C Uso de terapia antiplaquetária e/ou anticoagulante em pacientes com síndrome coronária aguda, mesmo com plaquetopenia IIa C Uso de dose reduzida de enoxaparina e heparina não fracionada em pacientes com contagem de plaquetas < 50.000. Monitorização de alvo terapêutico IIa C 1. Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C, et al. Risk of bleeding in patients with acute myocardial infarction treatedwith different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374(9706):1967-74. 2. HansenML,SorensenR,ClausenMT,Fog-PetersenML,Raunso J,Gadsboll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch InternMed. 2010;170(16):1433-41. 3. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, BrueckmannM, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-TermAnticoagulation Therapy (RE-LY) trial. Circulation. 2013;127(5):634-40. 4. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al; RE- DEEM Investigators.Dabigatranvs.placebo inpatientswithacutecoronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32(22):2781-9. 5. Barnes GD, Gu X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, et al. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI (2) experience. Thromb Res. 2014;134(2):294-9. 6. Roldan V, Marin F, Manzano-Fernandez S, Gallego P, Vilchez JA, Valdes M, et al. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J AmColl Cardiol. 2013;62(23):2199-204. 7. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al; ESC ScientificDocumentGroup.2017ESC focusedupdateondualantiplatelet therapy in coronary artery disease developed in collaborationwith EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;53(1):34-78. 8. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA. 2016 ACC/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/ PCNA/SCAI/STS Guideline for the diagnosis andmanagement of patients with stable ischemic heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e123-55. Erratum in: Circulation. 2016;134(10):e192-4. 9. Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG. Dual Antiplatelet Therapy (DAPT) Study Investigators. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA. 2015;313(11):1113-21. Erratum in: JAMA. 2016;316(1):105; JAMA. 2015 Jun 2;313(21):2185. 10. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, et al; LEADERS FREE Investigators. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373(21):2038-47. 11. Hawn MT, Graham LA, Richman JS, Itani KM, Henderson WG, Maddox TM. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA. 2013;310(14):1462-72. Erratum in: JAMA. 2014;311(5):528. 12. Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G, et al; ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015;65(8):805-15. 13. Ariotti S, Adamo M, Costa F, Patialiakas A, Briguori C, Thury A, et al; ZEUS Investigators. Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention?: A pre-specified analysis from the ZEUS trial. JACC Cardiovasc Interv. 2016;9(5):426-36. 14. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126(10):1185-93. 15. LambertsM, GislasonGH, Olesen JB, Kristensen SL, SchjerningOlsen AM, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013;62(11):981-9. 16. DewildeWJ,OirbansT,VerheugtFW,Kelder JC,DeSmetBJ,Herrman JP,et al; WOEST Study Investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention:anopen-label,randomised,controlledtrial.Lancet. 2013;381(9872):1107-15. 17. Fiedler KA, MaengM, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol. 2015;65(16):1619-29. 18. Gibson CM, Pinto DS, Chi G, Arbetter D, Yee M, Mehran R, et al. Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treatedwith two treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy. Circulation. 2017;135(4):323-33. 19. Cannon CP, Bhatt DL, Oldgren J, Lip GY, Ellis SG, Kimura T, et al; RE- DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513-1524. Referências 130